Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12162264 | 0.79 | TXNRD1 (0.40) | PARP1 | |
| SCHEMBL4816989 | 0.75 | MAPT (0.32) | KDM1AKDM4EALDH1A1LMNAGAA | |
| SCHEMBL24258213 | 0.73 | CD44 (0.36) | PARP1KDM1ACD44KDM4EMEN1 | |
| SCHEMBL30791259 | 0.72 | CD44 (0.35) | PARP1KDM1ACD44KDM4EMEN1 | |
| SCHEMBL23356013 | 0.72 | CD44 (0.35) | PARP1KDM1ACD44KDM4EMEN1 | |
| SCHEMBL9507986 | 0.72 | ALDH1A1 (0.38) | PARP1KDM1ACD44KDM4EMEN1 | |
| SCHEMBL12162261 | 0.71 | ALDH1A1 (0.32) | ALDH1A1MAPT | |
| SCHEMBL21936668 | 0.70 | CD44 (0.34) | PARP1KDM1ACD44KDM4EMEN1 | |
| SCHEMBL24258173 | 0.67 | KDM1A (0.35) | PARP1KDM1ACD44KDM4EMEN1 | |
| SCHEMBL24258225 | 0.67 | KDM1A (0.35) | PARP1KDM1ACD44KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | PARP1 1111/4885KDM1A 1866/4885CD44 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.